Synthetic Biologics, Inc. (SYN) Short Interest Down 10.2% in November

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 5,632,047 shares, a decrease of 10.2% from the November 15th total of 6,268,579 shares. Currently, 4.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 710,788 shares, the short-interest ratio is presently 7.9 days.

Synthetic Biologics (SYN) opened at $0.53 on Tuesday. Synthetic Biologics has a twelve month low of $0.41 and a twelve month high of $1.05.

Synthetic Biologics (NYSEAMERICAN:SYN) last released its earnings results on Wednesday, November 1st. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.10).

Several research firms recently commented on SYN. ValuEngine raised shares of Synthetic Biologics from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th. Zacks Investment Research lowered shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, BidaskClub lowered shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $3.92.

WARNING: “Synthetic Biologics, Inc. (SYN) Short Interest Down 10.2% in November” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply